Multivariable regression models of entire study cohort (dichotomized early peri-HCT MRD dynamics)
| . | Relapse . | RFS . | OS . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Early peri-HCT MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDneg/MRDpos | — | — | — | — | 5.31 (3.11-9.07) | <.001 | — | — |
| MRDpos/MRDneg | 4.34 (3.16-5.95) | <.001 | 3.06 (2.35-3.98) | <.001 | 2.45 (1.87-3.22) | <.001 | 1.36 (0.81-2.28) | .25 |
| MRDpos/MRDpos | 8.06 (5.27-12.34) | <.001 | 5.77 (3.95-8.43) | <.001 | 3.07 (2.07-4.55) | <.001 | 2.17 (0.82-5.74) | .12 |
| Post-HCT PB CD3 chimerism | ||||||||
| Full | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Mixed | 1.43 (1.02-2.02) | .037 | 1.19 (0.91-1.56) | .20 | 0.94 (0.72-1.25) | .68 | 0.90 (0.57-1.41) | .63 |
| Conditioning intensity | ||||||||
| MAC | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Non-MAC | 1.37 (0.97-1.94) | .073 | 1.57 (1.20-2.06) | .001 | 1.54 (1.16-2.05) | .003 | 1.81 (1.16-2.82) | .0093 |
| Disease status | ||||||||
| First remission | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Second remission | 1.39 (1.01-1.91) | .040 | 1.39 (1.08-1.77) | .0091 | 1.35 (1.05-1.73) | .019 | 1.45 (0.98-2.14) | .064 |
| Cytogenetic risk | ||||||||
| Favorable/intermediate | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Adverse | 1.58 (1.11-2.25) | .011 | 1.14 (0.86-1.51) | .38 | 1.23 (0.93-1.63) | .15 | 0.53 (0.31-0.92) | .024 |
| Age at HCT (per 10 y) | 0.96 (0.86-1.06) | .43 | 1.04 (0.96-1.14) | .33 | 1.06 (0.96-1.16) | .26 | 1.27 (1.07-1.49) | .0052 |
| WBC at diagnosis | 1.00 (1.00-1.00) | .041 | 1.00 (1.00-1.00) | .0032 | 1.00 (1.00-1.00) | .0062 | 1.00 (1.00-1.01) | .034 |
| HCT comorbidity index | ||||||||
| 0-1 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| 2-3 | 0.93 (0.68-1.26) | .62 | 1.01 (0.78-1.29) | .95 | 1.07 (0.82-1.39) | .62 | 1.23 (0.80-1.89) | .35 |
| ≥4 | 1.04 (0.74-1.45) | .82 | 1.12 (0.86-1.47) | .39 | 1.21 (0.92-1.59) | .17 | 1.31 (0.84-2.04) | .24 |
| Type of AML | ||||||||
| De novo | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Secondary | 0.80 (0.59-1.09) | .15 | 0.92 (0.72-1.17) | .49 | 0.99 (0.78-1.27) | .96 | 1.19 (0.81-1.75) | .37 |
| Pre-HCT karyotype | ||||||||
| Normalized | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not normalized | 1.75 (1.23-2.49) | .002 | 1.65 (1.23-2.22) | <.001 | 1.39 (1.03-1.89) | .034 | 1.44 (0.85-2.46) | .18 |
| Pre-HCT blood counts* | ||||||||
| Recovered | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not recovered | 0.83 (0.61-1.12) | .22 | 0.96 (0.76-1.21) | .73 | 1.12 (0.89-1.41) | .35 | 1.30 (0.90-1.89) | .16 |
| Stem cell source | ||||||||
| PB | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| BM | 1.67 (1.10-2.55) | .016 | 1.46 (1.02-2.11) | .040 | 1.30 (0.89-1.89) | .18 | 0.90 (0.42-1.91) | .78 |
| UCB | 0.91 (0.59-1.41) | .69 | 1.02 (0.73-1.43) | .90 | 1.09 (0.78-1.53) | .60 | 1.31 (0.77-2.22) | .32 |
| . | Relapse . | RFS . | OS . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Early peri-HCT MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDneg/MRDpos | — | — | — | — | 5.31 (3.11-9.07) | <.001 | — | — |
| MRDpos/MRDneg | 4.34 (3.16-5.95) | <.001 | 3.06 (2.35-3.98) | <.001 | 2.45 (1.87-3.22) | <.001 | 1.36 (0.81-2.28) | .25 |
| MRDpos/MRDpos | 8.06 (5.27-12.34) | <.001 | 5.77 (3.95-8.43) | <.001 | 3.07 (2.07-4.55) | <.001 | 2.17 (0.82-5.74) | .12 |
| Post-HCT PB CD3 chimerism | ||||||||
| Full | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Mixed | 1.43 (1.02-2.02) | .037 | 1.19 (0.91-1.56) | .20 | 0.94 (0.72-1.25) | .68 | 0.90 (0.57-1.41) | .63 |
| Conditioning intensity | ||||||||
| MAC | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Non-MAC | 1.37 (0.97-1.94) | .073 | 1.57 (1.20-2.06) | .001 | 1.54 (1.16-2.05) | .003 | 1.81 (1.16-2.82) | .0093 |
| Disease status | ||||||||
| First remission | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Second remission | 1.39 (1.01-1.91) | .040 | 1.39 (1.08-1.77) | .0091 | 1.35 (1.05-1.73) | .019 | 1.45 (0.98-2.14) | .064 |
| Cytogenetic risk | ||||||||
| Favorable/intermediate | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Adverse | 1.58 (1.11-2.25) | .011 | 1.14 (0.86-1.51) | .38 | 1.23 (0.93-1.63) | .15 | 0.53 (0.31-0.92) | .024 |
| Age at HCT (per 10 y) | 0.96 (0.86-1.06) | .43 | 1.04 (0.96-1.14) | .33 | 1.06 (0.96-1.16) | .26 | 1.27 (1.07-1.49) | .0052 |
| WBC at diagnosis | 1.00 (1.00-1.00) | .041 | 1.00 (1.00-1.00) | .0032 | 1.00 (1.00-1.00) | .0062 | 1.00 (1.00-1.01) | .034 |
| HCT comorbidity index | ||||||||
| 0-1 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| 2-3 | 0.93 (0.68-1.26) | .62 | 1.01 (0.78-1.29) | .95 | 1.07 (0.82-1.39) | .62 | 1.23 (0.80-1.89) | .35 |
| ≥4 | 1.04 (0.74-1.45) | .82 | 1.12 (0.86-1.47) | .39 | 1.21 (0.92-1.59) | .17 | 1.31 (0.84-2.04) | .24 |
| Type of AML | ||||||||
| De novo | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Secondary | 0.80 (0.59-1.09) | .15 | 0.92 (0.72-1.17) | .49 | 0.99 (0.78-1.27) | .96 | 1.19 (0.81-1.75) | .37 |
| Pre-HCT karyotype | ||||||||
| Normalized | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not normalized | 1.75 (1.23-2.49) | .002 | 1.65 (1.23-2.22) | <.001 | 1.39 (1.03-1.89) | .034 | 1.44 (0.85-2.46) | .18 |
| Pre-HCT blood counts* | ||||||||
| Recovered | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not recovered | 0.83 (0.61-1.12) | .22 | 0.96 (0.76-1.21) | .73 | 1.12 (0.89-1.41) | .35 | 1.30 (0.90-1.89) | .16 |
| Stem cell source | ||||||||
| PB | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| BM | 1.67 (1.10-2.55) | .016 | 1.46 (1.02-2.11) | .040 | 1.30 (0.89-1.89) | .18 | 0.90 (0.42-1.91) | .78 |
| UCB | 0.91 (0.59-1.41) | .69 | 1.02 (0.73-1.43) | .90 | 1.09 (0.78-1.53) | .60 | 1.31 (0.77-2.22) | .32 |
ANC, absolute neutrophil count; BM, bone marrow; CI, confidence interval; HR, hazard ratio; PB, peripheral blood; UCB, umbilical cord blood.
Recovered: ANC ≥ 1000/µL and platelets ≥ 100 000/µL; not recovered: ANC < 1000/µL and/or platelets < 100 000/µL.